TICKERNOMICS Sign up
Last Update: 2024-12-27 15:30:52
Briacell Therapeutics Corp ( BCT.TO ) https://www.briacell.com
0.53USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Canada
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-90.34%
BCT.TO
SPY
32.66%
-94.29%
BCT.TO
SPY
108.59%
-94.25%
BCT.TO
SPY
302.52%
-98.73%
BCT.TO
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
9.21
8.27
0.02
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.54
0.00
-1.48
-31.89
0.00
-0.22
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.5088
-63.54
-176.65
1.41
Other Earnings and Cash Flow Stats:
Briacell Therapeutics Corp ( BCT.TO ) Net Income TTM ($MM) is -6.00
Briacell Therapeutics Corp ( BCT.TO ) Operating Income TTM ($MM) is -35.27
Briacell Therapeutics Corp ( BCT.TO ) Owners' Earnings Annual ($MM) is 0.00
Briacell Therapeutics Corp ( BCT.TO ) Current Price to Owners' Earnings ratio is 0.00
Briacell Therapeutics Corp ( BCT.TO ) EBITDA TTM ($MM) is -35.25
Briacell Therapeutics Corp ( BCT.TO ) EBITDA Margin is 0.00%
Capital Allocation:
Briacell Therapeutics Corp ( BCT.TO ) has paid 0.00 dividends per share and bought back 0.693165 million shares in the past 12 months
Briacell Therapeutics Corp ( BCT.TO ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Briacell Therapeutics Corp ( BCT.TO ) Interest-bearing Debt ($MM) as of last quarter is 0
Briacell Therapeutics Corp ( BCT.TO ) Annual Working Capital Investments ($MM) are -4
Briacell Therapeutics Corp ( BCT.TO ) Book Value ($MM) as of last quarter is -7
Briacell Therapeutics Corp ( BCT.TO ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Briacell Therapeutics Corp ( BCT.TO ) has 0 million in cash on hand as of last quarter
Briacell Therapeutics Corp ( BCT.TO ) has 6 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Briacell Therapeutics Corp ( BCT.TO ) has 15 common shares outstanding as of last quarter
Briacell Therapeutics Corp ( BCT.TO ) has 0 million USD of preferred stock value
Academic Scores:
Briacell Therapeutics Corp ( BCT.TO ) Altman Z-Score is -38.44 as of last quarter
Briacell Therapeutics Corp ( BCT.TO ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Briacell Therapeutics Corp ( BCT.TO ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Briacell Therapeutics Corp ( BCT.TO ) for the amount of $ on
14.33% of Briacell Therapeutics Corp ( BCT.TO ) is held by insiders, and 4.65% is held by institutions
Briacell Therapeutics Corp ( BCT.TO ) went public on 1970-01-01
Other Briacell Therapeutics Corp ( BCT.TO ) financial metrics:
FCF:-31.01
Unlevered Free Cash Flow:0.00
EPS:0.43
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-115.05
Beta:1.41
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Briacell Therapeutics Corp ( BCT.TO ) :
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.